Acadia Pharmaceuticals Inc (ACAD) Actualités

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Ryan Reynolds Announces More to Parkinson’s® Campaign

-- The national disease awareness campaign aims to educate and drive conversation about recognizing and...

Form 4 - Statement of changes in beneficial ownership of securities

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth Conference

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Canaccord Genuity 44th Annual...

Form 8-K - Current report

Acadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview

- Second quarter total net product sales of $242.0 million, up 46% year-over-year Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its...

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2024

Company to host conference call and webcast on Tuesday, August 6, 2024, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD...

Clinical Data from Open-Label Extension LILAC-1™ and LILAC-2™ Studies Evaluating Long-Term Safety and Efficacy of DAYBUE™ (trofinetide) in Patients with Rett Syndrome Published in Med

-- Continued Improvements in RSBQ and CGI-I scores seen with long-term DAYBUE treatment in Phase 3 LAVENDER™ and LILAC studies -- DAYBUE safety...

Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting

Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be presented at...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities